You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES

HIGHLIGHTS

EVENTS

ISTH, Kedrion supports symposium on the importance of inhibitor eradication

The central theme of the round table will be the optimization of the treatment of patients with Hemophilia A

read more 

EVENTS

Kedrion supports the World Federation Of Hemophilia Virtual Summit 2020

The company reaffirms its commitment to the patient community during the COVID-19 epidemic

read more 

CORPORATE

Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel

The two companies are now working to expand the Clinical Development Program to the US

read more 
  1. EVENTS - 07-12-2015

    Hemophilia A. SIPPET study selected by the American Society of Hematology

    Presented at the ASH Congress in Orlando, it was chosen from amongst approximately three thousand studies

    read more 
  2. EVENTS - 09-11-2015

    Kedrion among the key players of Farmindustria's roadshow in Siena

    The Lucca-based company presented as one of the innovative pharmaceutical companies in Tuscany

    read more 
  3. CORPORATE - 12-10-2015

    Kedrion supports Fondazione Paracelso's activities in Afghanistan

    Kedrion confirms its commitment to broaden access to hemophilia treatments in developing Countries

    read more 
  4. CORPORATE - 29-09-2015

    Kedrion Notes 2019 Tender Offer results

    Kedrion has accepted for purchase Notes validly tendered for a total aggregate principal amount equal to €150,716,000

    read more 

Pages

For more information please contact: pressoffice@kedrion.com